Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -42.82%. A quarter ago, it was expected that this company would post earnings of $0.16 per share when it actually produced earnings of $0.12, delivering a surprise of -25%.Over the last four quarters, the com ...

Core Viewpoint - Voyager Therapeutics, Inc. (NASDAQ:VYGR) is recognized as a promising micro-cap stock by analysts, particularly following its strong Q3 performance and significant cash reserves [1][2]. Financial Performance - Voyager reported a loss per share of $0.47 for Q3 2025, which was $0.05 better than analyst expectations [3]. - The company's revenue for the quarter exceeded $13 million, representing a nearly 45% decline compared to the same period last year, but it surpassed market estimates by $5.5 million [3]. - Voyager ended the quarter with $229 million in cash, providing operational runway into 2028, and remains eligible for up to $2.4 billion in partner milestones [2]. Analyst Coverage - HC Wainwright has lowered the price target for Voyager from $30 to $25 while maintaining a Buy rating on the shares, reflecting confidence in the company's future despite the price adjustment [2]. Company Focus - Voyager Therapeutics is a biotechnology company that specializes in human genetics aimed at curing neurological diseases [4].

Core Insights - uniQure N.V. is a biotechnology company focused on developing gene therapies for severe genetic diseases, competing with firms like REGENXBIO, Voyager Therapeutics, Ultragenyx Pharmaceutical, and Blueprint Medicines [1] Financial Performance - uniQure has a Return on Invested Capital (ROIC) of -23.80% and a Weighted Average Cost of Capital (WACC) of 11.72%, indicating it generates returns below its cost of capital [2][6] - REGENXBIO has a ROIC of -37.81% and a WACC of 9.78%, resulting in a ROIC to WACC ratio of -3.87, showing lower efficiency than uniQure [3] - Voyager Therapeutics has a ROIC of -42.29% and a WACC of 8.67%, leading to a ROIC to WACC ratio of -4.88, further emphasizing the profitability challenges in the biotech sector [3] - Ultragenyx Pharmaceutical has a ROIC of -63.41% and a WACC of 6.50%, with a ROIC to WACC ratio of -9.76, indicating significant inefficiency [4] - Blueprint Medicines Corporation has a ROIC of -17.59% and a WACC of 8.26%, resulting in a ROIC to WACC ratio of -2.13, which is the closest to breaking even among the analyzed peers [4][5] Comparative Analysis - All companies analyzed are generating returns below their cost of capital, but Blueprint Medicines Corporation shows the highest potential for improvement in ROIC relative to its WACC [5][6]

Core Insights - uniQure N.V. is a biotechnology company focused on developing gene therapies for genetic disorders, aiming for long-term patient benefits in rare diseases [1] - The company faces competition from other biotech firms such as REGENXBIO Inc., Voyager Therapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Blueprint Medicines Corporation [1] Financial Performance - uniQure's Return on Invested Capital (ROIC) is -23.80%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 10.24%, resulting in a ROIC to WACC ratio of -2.32 [2] - Compared to its peers, REGENXBIO Inc. has a ROIC of -37.81% and a WACC of 9.85%, leading to a ROIC to WACC ratio of -3.84, indicating lower capital efficiency than uniQure [3] - Voyager Therapeutics, Inc. reports a ROIC of -42.29% against a WACC of 8.58%, resulting in a ROIC to WACC ratio of -4.93, showing even lower capital efficiency [3] - Ultragenyx Pharmaceutical Inc. has a ROIC of -63.41% and a WACC of 6.61%, leading to a ROIC to WACC ratio of -9.59, the least favorable among peers [4] - Blueprint Medicines Corporation achieves a ROIC of -17.59% and a WACC of 8.26%, resulting in a ROIC to WACC ratio of -2.13, the best among the group but still negative [4] Industry Challenges - All companies analyzed are currently operating at a loss relative to their cost of capital, highlighting the challenges biotech companies face in achieving profitability and efficient capital utilization in the competitive gene therapy landscape [5]

Core Insights - Moderna reported a quarterly loss of $0.51 per share, significantly better than the Zacks Consensus Estimate of a loss of $2.15, representing an earnings surprise of +76.28% [1] - The company generated revenues of $1.02 billion for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 18.13%, although this is a decline from $1.86 billion in the same quarter last year [2] - Moderna has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] Financial Performance - The earnings report indicates a loss of $0.51 per share compared to a profit of $0.03 per share a year ago, adjusted for non-recurring items [1] - The company has shown a mixed trend in estimate revisions ahead of the earnings release, currently holding a Zacks Rank 3 (Hold), suggesting expected performance in line with the market [6] - Current consensus EPS estimate for the upcoming quarter is -$2.90 on revenues of $805.49 million, and for the current fiscal year, it is -$9.74 on revenues of $1.9 billion [7] Market Context - Moderna shares have declined approximately 43.3% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The Medical - Biomedical and Genetics industry, to which Moderna belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - The performance of Moderna's stock may also be influenced by the earnings outlook and trends in earnings estimate revisions, which have shown a strong correlation with near-term stock movements [5]

Core Insights - Voyager Therapeutics is advancing two preclinical programs targeting tau for Alzheimer's disease treatment, specifically the tau silencing gene therapy VY1706 and the anti-tau antibody VY7523 [1][2] Group 1: VY1706 Tau Silencing Gene Therapy - A single intravenous (IV) administration of VY1706 resulted in a dose-dependent reduction of tau mRNA by 44% to 73% and tau protein by 27% to 55% in a non-human primate study, with effects sustained for up to three months [4] - The therapy demonstrated broad distribution across brain regions affected by Alzheimer's disease, including the hippocampus and frontal cortex, while liver targeting was reduced by approximately 30-fold compared to wild type AAV9 [4][8] - VY1706 is currently in Investigational New Drug (IND)-enabling studies, with an IND filing anticipated in 2026 [4][8] Group 2: VY7523 Anti-Tau Antibody - Preclinical data indicate that the murine version of VY7523 selectively binds to pathological tau tangles and effectively reduces tau spread in a P301S mouse model [5][9] - VY7523 has shown approximately 70% inhibition of pathological tau spread in preclinical studies and is currently being evaluated in a multiple ascending dose trial for early Alzheimer's disease patients [9] - Initial tau positron emission tomography (PET) imaging data for VY7523 is expected in the second half of 2026 [5][9] Group 3: Upcoming Events and Presentations - Voyager will present data on both therapies at the AD/PD™ 2025 conference in Vienna from April 1-5, 2025, and will host a live webcast on April 7, 2025, to recap key findings [1][7] - Dr. Toby Ferguson, Chief Medical Officer, will participate in two panels discussing anti-tau therapies and drug development challenges at the conference [6]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against four companies: Dave, Inc., Red Cat Holdings, Inc., Perpetua Resources Corp., and Voyager Therapeutics, Inc. for possible violations of federal securities laws and other unlawful business practices [1] Company Summaries Dave, Inc. (NASDAQ: DAVE) - The Justice Department and FTC announced a civil enforcement action against Dave, Inc. and its CEO Jason Wilk for alleged violations of the FTC Act and ROSCA, claiming misleading advertising regarding cash advances, hidden fees, and recurring monthly fees without a cancellation mechanism [2] - Following the announcement, Dave shares opened at $84.00 on December 31, 2024, reflecting a drop of over 10% from the previous day [3] Red Cat Holdings, Inc. (NASDAQ: RCAT) - Kerrisdale Capital published a report alleging that Red Cat overstated the revenue potential of its U.S. Army SRR drone contract and lacks the production capacity to fulfill its promises, raising concerns about executive departures and insider transactions [4] - As a result, Red Cat's stock price fell by $2.36 per share, or 21.63%, closing at $8.55 per share on January 17, 2025 [4] Perpetua Resources Corp. (NASDAQ: PPTA) - The investigation focuses on whether Perpetua issued false or misleading statements and failed to disclose pertinent information. The company released an updated cash flow model for the Stibnite Gold Project, indicating increased capital expenditures and costs, but improved economic metrics due to rising commodity prices [5] - Following this news, shares of Perpetua fell by 22.3% on February 14, 2025 [5] Voyager Therapeutics, Inc. (NASDAQ: VYGR) - Voyager announced it would assess alternate payloads for its gene therapy program for ALS, stating that emerging preclinical data indicated issues with the siRNA payload component of VY9323, which does not meet their standards [6] - Consequently, Voyager's stock price dropped by $1.11 per share, or 20.86%, closing at $4.21 per share on February 11, 2025 [6]